All In Biotech

Drug Trial Radar · NCT03959527

Zoliflodacin in Uncomplicated Gonorrhoea

A Multi-center, Randomized, Open-label, Non Inferiority Trial to Evaluate the Efficacy and Safety of a Single, Oral Dose of Zoliflodacin Compared to a Combination of a Single Intramuscular Dose of Ceftriaxone and a Single Oral Dose of Azithromycin in the Treatment of Patients With Uncomplicated Gonorrhoea

Last checked: Nov 20, 2026Latest source record: Oct 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,011 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,011

Actual

Start

Nov 6, 2019

Primary completion

Aug 30, 2023

Study completion Sep 18, 2023

Sponsor

Lead sponsor
Global Antibiotics Research and Development PartnershipAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multi-center, open label, randomized controlled, non-inferiority phase III trial evaluating the safety and efficacy of a 3 g oral dose of zoliflodacin compared to a combination of a single intra-muscular 500 mg dose of ceftriaxone and a single 1 g oral dose of azithromycin for the treatment of uncomplicated gonorrhoea.

Conditions

  • Gonorrhea

Interventions

  • zoliflodacinDrug

    Dose: 3g, oral administration

  • ceftriaxoneDrug

    Dose: 500mg, Intra-Muscular (IM) administration

  • azithromycinDrug

    Dose: 1g, oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Microbiological Cure Rate for Zoliflodacin Compared to a Combination of a Single Dose of Ceftriaxone and Azithromycin.Time frame: Day 6 (+/- 2)

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • Jefferson County Department of Health

    Birmingham, Alabama

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • San Francisco Department Of Public Health City Clinic

    San Francisco, California

  • Bell Flower Clinic

    Indianapolis, Indiana

  • Louisiana State University Health Sciences Center

    New Orleans, Louisiana

  • Public Health - Seattle & King County STD Clinic

    Seattle, Washington

  • Institute of Tropical Medicine

    Antwerp, Belgium

  • Public Health Service (GGD) Amsterdam / STI Outpatient Clinic

    Amsterdam, Netherlands

  • SAMRC Botha's Hill Clinical Research Site

    Bothas Hill, South Africa

  • Masiphumelele Research Site

    Cape Town, South Africa

  • Ndlovu Research Centre

    Elandsdoorn, South Africa

  • Wits RHI

    Johannesburg, South Africa

  • Setshaba Research Centre

    Soshanguve, South Africa

  • SAMRC Tongaat Clinical Research Site

    Tongaat, South Africa

  • Bangrak STI Center

    Bangkok, Thailand

  • Institute of HIV Research and Innovation

    Bangkok, Thailand

  • Silom Community Clinic

    Bangkok, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.